New drug shows promise in treating indolent non-Hodgkin lymphomas Fred Hutchinson Cancer Research Center News About 20,000 people in the United States were diagnosed with iNHL in 2012 and approximately 7,000 died of the disease. The standard treatment for iNHL is a combination of rituximab, a drug that targets the protein CD20 found on B cells, and ... |
